FY2022 Earnings Estimate for Insulet Co. (NASDAQ:PODD) Issued By William Blair

Insulet Co. (NASDAQ:PODDGet Rating) – Stock analysts at William Blair upped their FY2022 earnings estimates for shares of Insulet in a note issued to investors on Monday, November 21st. William Blair analyst M. Kaczor now anticipates that the medical instruments supplier will post earnings of $0.89 per share for the year, up from their prior forecast of $0.69. The consensus estimate for Insulet’s current full-year earnings is $1.00 per share. William Blair also issued estimates for Insulet’s Q1 2023 earnings at $0.04 EPS, Q2 2023 earnings at $0.07 EPS and FY2023 earnings at $0.87 EPS.

A number of other research firms have also issued reports on PODD. Canaccord Genuity Group boosted their price target on shares of Insulet from $290.00 to $310.00 and gave the company a “buy” rating in a report on Friday, November 4th. Citigroup boosted their price target on shares of Insulet from $260.00 to $270.00 in a report on Friday, November 4th. Piper Sandler upgraded shares of Insulet from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $235.00 to $340.00 in a report on Friday, November 4th. Canaccord Genuity Group boosted their price objective on shares of Insulet from $250.00 to $290.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, StockNews.com raised shares of Insulet from a “sell” rating to a “hold” rating in a research report on Wednesday, November 9th. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $300.62.

Insulet Stock Up 1.0 %

PODD stock opened at $292.63 on Wednesday. Insulet has a 52-week low of $181.00 and a 52-week high of $320.00. The company’s 50 day simple moving average is $256.02 and its 200-day simple moving average is $241.87. The company has a debt-to-equity ratio of 3.22, a current ratio of 3.98 and a quick ratio of 3.00. The firm has a market capitalization of $20.32 billion, a P/E ratio of 1,219.29 and a beta of 0.79.

Hedge Funds Weigh In On Insulet

Several large investors have recently bought and sold shares of PODD. Park Avenue Securities LLC acquired a new position in Insulet during the 1st quarter valued at $211,000. Signaturefd LLC raised its stake in shares of Insulet by 41.0% in the 1st quarter. Signaturefd LLC now owns 378 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 110 shares in the last quarter. Atria Investments LLC acquired a new position in shares of Insulet in the 1st quarter valued at $1,103,000. FDx Advisors Inc. acquired a new position in shares of Insulet in the 1st quarter valued at $206,000. Finally, Arizona State Retirement System raised its stake in shares of Insulet by 2.4% in the 1st quarter. Arizona State Retirement System now owns 19,198 shares of the medical instruments supplier’s stock valued at $5,114,000 after buying an additional 446 shares in the last quarter.

Insiders Place Their Bets

In other news, SVP Dan Manea sold 200 shares of the business’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $294.62, for a total value of $58,924.00. Following the completion of the sale, the senior vice president now directly owns 3,158 shares in the company, valued at $930,409.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Shacey Petrovic sold 15,000 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $231.80, for a total transaction of $3,477,000.00. Following the completion of the transaction, the director now directly owns 13,695 shares in the company, valued at approximately $3,174,501. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Dan Manea sold 200 shares of the company’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $294.62, for a total transaction of $58,924.00. Following the transaction, the senior vice president now owns 3,158 shares of the company’s stock, valued at $930,409.96. The disclosure for this sale can be found here. Insiders sold 28,858 shares of company stock valued at $7,756,109 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Read More

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.